TY - JOUR
T1 - Activity of 2-acetylpyridine and 2 acetylquinoline thiosemicarbazones tested in vitro in combination with other antituberculous drugs
AU - Collins, F. M.
AU - Klayman, D. L.
AU - Morrison, N. E.
PY - 1982
Y1 - 1982
N2 - Determinations of minimal inhibitory concentrations (MIC) were carried out using three new 2 acetylpyridine and two new 2-acetylquinoline thiosemicarbazones tested against Mycobacterium tuberculosis, M. kansasii, M. simiae, M. avium, and M. intracellulare. Two of the compounds (Compounds L 31) 30) exhibited MIC ≤ 5 μg per ml for all of the test organisms, except for M. simiae, which was resistant to antituberculous drugs. The other thiosemicarbazones (Compounds 3L, 2N, 3G, and 2H) were relatively inactive against the nontuberculous mycobacteria. Rifampin, amikacin, and clofazimine were active when tested singly or in combination with Compounds L and 31. Addition of compound 31 to a mixture of rifampin, amikacin, and clofazimine resulted in combination MIC of less than 0.6 μg/mg against all of the nontuberculous mycobacteria, suggesting that combinations of this type may be suitable for the treatment of infections caused by these highly drug resistant organisms.
AB - Determinations of minimal inhibitory concentrations (MIC) were carried out using three new 2 acetylpyridine and two new 2-acetylquinoline thiosemicarbazones tested against Mycobacterium tuberculosis, M. kansasii, M. simiae, M. avium, and M. intracellulare. Two of the compounds (Compounds L 31) 30) exhibited MIC ≤ 5 μg per ml for all of the test organisms, except for M. simiae, which was resistant to antituberculous drugs. The other thiosemicarbazones (Compounds 3L, 2N, 3G, and 2H) were relatively inactive against the nontuberculous mycobacteria. Rifampin, amikacin, and clofazimine were active when tested singly or in combination with Compounds L and 31. Addition of compound 31 to a mixture of rifampin, amikacin, and clofazimine resulted in combination MIC of less than 0.6 μg/mg against all of the nontuberculous mycobacteria, suggesting that combinations of this type may be suitable for the treatment of infections caused by these highly drug resistant organisms.
UR - http://www.scopus.com/inward/record.url?scp=0020043327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020043327&partnerID=8YFLogxK
M3 - Article
C2 - 6175259
AN - SCOPUS:0020043327
SN - 0003-0805
VL - 125
SP - 58
EP - 60
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
IS - 1
ER -